We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

TB Protein Structure Determination Opens Therapeutic Opportunities

TB Protein Structure Determination Opens Therapeutic Opportunities

TB Protein Structure Determination Opens Therapeutic Opportunities

TB Protein Structure Determination Opens Therapeutic Opportunities

The mycobacterial ESX-5 secretion system is located in the bacterial inner membrane and consists of six units, which assemble into a symmetrical structure with a pore at the centre. Credit: Isabel Romero Calvo/EMBL.
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TB Protein Structure Determination Opens Therapeutic Opportunities"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tuberculosis is one of the top ten causes of death worldwide, infecting about one-quarter of the world’s population. Although it is treatable, the rise of multidrug-resistant tuberculosis poses a major threat to global health security, and has been declared by the World Health Organization as a global health emergency. Reduced access to diagnosis and treatment during the COVID-19 pandemic is expected to dramatically increase the number of tuberculosis infections. This will set global efforts to tackle the disease back several years.

Tuberculosis is caused by infection with Mycobacterium tuberculosis: a bacterium that infects human lungs and other organs by using complex molecular machineries. These include protein complexes known as type VII secretion systems, which enable M. tuberculosis to release molecules into its host, which disarm and ultimately kill the infected human cell. Five such secretion systems, labelled ESX-1 to ESX-5, are found among M. tuberculosis and other closely related mycobacteria, many of which are pathogenic. Without them, the bacteria are unable to infect human cells.

The Wilmanns group at EMBL Hamburg has been using high-resolution structural biology to study mycobacterial proteins for the last two decades. The molecular understanding of the bacterial machinery used to infect cells resulted in collaborations with industry to develop new drugs against tuberculosis. In their most recent study, they determined the molecular structure of the secretion system ESX-5 to a high level of detail. They saw that the core of ESX-5 is built of 30 protein units, which form a dynamic membrane pore to allow secretion of proteins that enable the bacterium to survive and multiply inside human cells. Knowledge of the ESX-5 structure at high-resolution is essential to target specific sites with small-molecule drugs.

“Our new structure of the ESX-5 secretion complex provides deep insight into a major sluice gate that separates the inner of these bacteria from the outer host environment. Opening this gate allow the pathogen to spit out its deadly weapons to infect humans to develop tuberculosis. We can use this structure as a toolbox with literally thousands of potential drug targets. This will open an entirely new field of studies on tuberculosis,” says Matthias Wilmanns, who leads the study. Kate Beckham, who developed an innovative way to isolate ESX-5, adds: “The central pore we saw in ESX-5 could serve as a new drug target. Blocking it could prevent infection with pathogenic mycobacteria.”

The study could also help scientists to develop new vaccines for tuberculosis. The widely used Bacillus Calmette–Guérin (BCG) vaccine, which has its 100th anniversary this year, is based on a strain of mycobacterium that has lost its ability to cause disease because of a defect in the ESX-1 system. However, as BCG vaccination offers insufficient protection and is most effective in young infants only, alternative vaccines are urgently needed. Due to its close structural and functional relation with ESX-1, targeting the ESX-5 secretion system might spur the development of new vaccines that could complement or replace those currently used.

Determining the molecular structure of ESX-5 was particularly challenging because of its large size and complexity. No single structural biology method can provide the full picture. In this case, the key to success was using integrative structural biology, in which data obtained using different methods – cryo-electron microscopy, X-ray crystallography, mass spectrometry and computational methods – were used jointly to create a coherent model.

“Eighteen months ago, solving this structure looked like mission: impossible,” says Matthias Wilmanns. “We managed to put the puzzle pieces together because each team member contributed unique expertise. To solve the complete structure, we collaborated with Jan Kosinski’s group at EMBL Hamburg and the Centre for Structural Systems Biology, which provided necessary expertise in integrative structural biology. We also received great help from our colleagues at EMBL Heidelberg, who performed cryo-electron microscopy experiments.”

Beckham KSH, Ritter C, Chojnowski G, et al. Structure of the mycobacterial ESX-5 type VII secretion system pore complex. Sci Adv. 2021;7(26):eabg9923. doi:10.1126/sciadv.abg9923

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.